Global Respiratory Drugs

Respiratory Drugs Comprehensive Study by Type (Antiasthmatic combinations, Antihistamines, Antitussives, Bronchodilators, Others), Disease Type (Asthma, COPD, Allergic rhinitis, Cystic fibrosis, Idiopathic pulmonary fibrosis, Other respiratory disorders), End-users (Hospitals, Clinics, Others), Distribution Channel (Online Channel, Offline Channel) Players and Region - Global Market Outlook to 2026

Respiratory Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Respiratory Drugs Market?

Currently, more than 25 million people in the United States have asthma. Approximately 14.8 million adults have been diagnosed with COPD, and approximately 12 million people have not yet been diagnosed. Respiratory drugs are used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. These medicines are available in many different forms such as oral tablets, oral liquids, injections or inhalations.

The market study is being classified by Type (Antiasthmatic combinations, Antihistamines, Antitussives, Bronchodilators and Others) and major geographies with country level break-up.

GlaxoSmithKline (United Kingdom), Boehringer Ingelheim GmbH (Germany), 3M (United States), AstraZeneca plc (United Kingdom), Merck & Co., Inc. (United States), Novartis AG (Switzerland),, Omron Corporation (Japan) and Sunovion Pharmaceuticals Inc. (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Respiratory Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Respiratory Drugs market by Type, Application and Region.

On the basis of geography, the market of Respiratory Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Respiratory Diseases
  • Increased Pollution Around the Globe

Market Trend
  • Growing Focus on Preventive Healthcare
  • Increasing Number of Diagnostic Centers

Restraints
  • Side Effects of the Respiratory Drugs

Opportunities
  • Growing Number of Geriatric Population
  • Growing Healthcare Infrastructure In Developing Regions

Challenges
  • High Initial Investment


In December 2019, AstraZeneca has announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This is the first approval by the National Medical Products Administration for a triple-combination therapy in a pressurized metered-dose inhaler (pMDI), which uses the innovative Aerosphere delivery technology.


Key Target Audience
Respiratory Drug Manufacturers, Raw Material Suppliers, Distributors, Government Bodies and End-users

Report Objectives / Segmentation Covered

By Type
  • Antiasthmatic combinations
  • Antihistamines
  • Antitussives
  • Bronchodilators
  • Others
By Disease Type
  • Asthma
  • COPD
  • Allergic rhinitis
  • Cystic fibrosis
  • Idiopathic pulmonary fibrosis
  • Other respiratory disorders

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Online Channel
  • Offline Channel

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Respiratory Diseases
      • 3.2.2. Increased Pollution Around the Globe
    • 3.3. Market Challenges
      • 3.3.1. High Initial Investment
    • 3.4. Market Trends
      • 3.4.1. Growing Focus on Preventive Healthcare
      • 3.4.2. Increasing Number of Diagnostic Centers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Respiratory Drugs, by Type, Disease Type, End-users, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Respiratory Drugs (Value)
      • 5.2.1. Global Respiratory Drugs by: Type (Value)
        • 5.2.1.1. Antiasthmatic combinations
        • 5.2.1.2. Antihistamines
        • 5.2.1.3. Antitussives
        • 5.2.1.4. Bronchodilators
        • 5.2.1.5. Others
      • 5.2.2. Global Respiratory Drugs by: Disease Type (Value)
        • 5.2.2.1. Asthma
        • 5.2.2.2. COPD
        • 5.2.2.3. Allergic rhinitis
        • 5.2.2.4. Cystic fibrosis
        • 5.2.2.5. Idiopathic pulmonary fibrosis
        • 5.2.2.6. Other respiratory disorders
      • 5.2.3. Global Respiratory Drugs by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Respiratory Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Online Channel
        • 5.2.4.2. Offline Channel
      • 5.2.5. Global Respiratory Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Respiratory Drugs (Volume)
      • 5.3.1. Global Respiratory Drugs by: Type (Volume)
        • 5.3.1.1. Antiasthmatic combinations
        • 5.3.1.2. Antihistamines
        • 5.3.1.3. Antitussives
        • 5.3.1.4. Bronchodilators
        • 5.3.1.5. Others
      • 5.3.2. Global Respiratory Drugs by: Disease Type (Volume)
        • 5.3.2.1. Asthma
        • 5.3.2.2. COPD
        • 5.3.2.3. Allergic rhinitis
        • 5.3.2.4. Cystic fibrosis
        • 5.3.2.5. Idiopathic pulmonary fibrosis
        • 5.3.2.6. Other respiratory disorders
      • 5.3.3. Global Respiratory Drugs by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global Respiratory Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Online Channel
        • 5.3.4.2. Offline Channel
      • 5.3.5. Global Respiratory Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Respiratory Drugs (Price)
      • 5.4.1. Global Respiratory Drugs by: Type (Price)
  • 6. Respiratory Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim GmbH (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. 3M (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland),
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Omron Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sunovion Pharmaceuticals Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Respiratory Drugs Sale, by Type, Disease Type, End-users, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Respiratory Drugs (Value)
      • 7.2.1. Global Respiratory Drugs by: Type (Value)
        • 7.2.1.1. Antiasthmatic combinations
        • 7.2.1.2. Antihistamines
        • 7.2.1.3. Antitussives
        • 7.2.1.4. Bronchodilators
        • 7.2.1.5. Others
      • 7.2.2. Global Respiratory Drugs by: Disease Type (Value)
        • 7.2.2.1. Asthma
        • 7.2.2.2. COPD
        • 7.2.2.3. Allergic rhinitis
        • 7.2.2.4. Cystic fibrosis
        • 7.2.2.5. Idiopathic pulmonary fibrosis
        • 7.2.2.6. Other respiratory disorders
      • 7.2.3. Global Respiratory Drugs by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Respiratory Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Online Channel
        • 7.2.4.2. Offline Channel
      • 7.2.5. Global Respiratory Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Respiratory Drugs (Volume)
      • 7.3.1. Global Respiratory Drugs by: Type (Volume)
        • 7.3.1.1. Antiasthmatic combinations
        • 7.3.1.2. Antihistamines
        • 7.3.1.3. Antitussives
        • 7.3.1.4. Bronchodilators
        • 7.3.1.5. Others
      • 7.3.2. Global Respiratory Drugs by: Disease Type (Volume)
        • 7.3.2.1. Asthma
        • 7.3.2.2. COPD
        • 7.3.2.3. Allergic rhinitis
        • 7.3.2.4. Cystic fibrosis
        • 7.3.2.5. Idiopathic pulmonary fibrosis
        • 7.3.2.6. Other respiratory disorders
      • 7.3.3. Global Respiratory Drugs by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global Respiratory Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Online Channel
        • 7.3.4.2. Offline Channel
      • 7.3.5. Global Respiratory Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Respiratory Drugs (Price)
      • 7.4.1. Global Respiratory Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Respiratory Drugs: by Type(USD Million)
  • Table 2. Respiratory Drugs Antiasthmatic combinations , by Region USD Million (2015-2020)
  • Table 3. Respiratory Drugs Antihistamines , by Region USD Million (2015-2020)
  • Table 4. Respiratory Drugs Antitussives , by Region USD Million (2015-2020)
  • Table 5. Respiratory Drugs Bronchodilators , by Region USD Million (2015-2020)
  • Table 6. Respiratory Drugs Others , by Region USD Million (2015-2020)
  • Table 7. Respiratory Drugs: by Disease Type(USD Million)
  • Table 8. Respiratory Drugs Asthma , by Region USD Million (2015-2020)
  • Table 9. Respiratory Drugs COPD , by Region USD Million (2015-2020)
  • Table 10. Respiratory Drugs Allergic rhinitis , by Region USD Million (2015-2020)
  • Table 11. Respiratory Drugs Cystic fibrosis , by Region USD Million (2015-2020)
  • Table 12. Respiratory Drugs Idiopathic pulmonary fibrosis , by Region USD Million (2015-2020)
  • Table 13. Respiratory Drugs Other respiratory disorders , by Region USD Million (2015-2020)
  • Table 14. Respiratory Drugs: by End-users(USD Million)
  • Table 15. Respiratory Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 16. Respiratory Drugs Clinics , by Region USD Million (2015-2020)
  • Table 17. Respiratory Drugs Others , by Region USD Million (2015-2020)
  • Table 18. Respiratory Drugs: by Distribution Channel(USD Million)
  • Table 19. Respiratory Drugs Online Channel , by Region USD Million (2015-2020)
  • Table 20. Respiratory Drugs Offline Channel , by Region USD Million (2015-2020)
  • Table 21. South America Respiratory Drugs, by Country USD Million (2015-2020)
  • Table 22. South America Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 23. South America Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 24. South America Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 25. South America Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 26. Brazil Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 27. Brazil Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 28. Brazil Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 29. Brazil Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 30. Argentina Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 31. Argentina Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 32. Argentina Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 33. Argentina Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 34. Rest of South America Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 36. Rest of South America Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 37. Rest of South America Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. Asia Pacific Respiratory Drugs, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 41. Asia Pacific Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 42. Asia Pacific Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 43. China Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 44. China Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 45. China Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 46. China Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. Japan Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 48. Japan Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 49. Japan Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 50. Japan Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. India Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 52. India Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 53. India Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 54. India Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 55. South Korea Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 56. South Korea Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 57. South Korea Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 58. South Korea Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 59. Taiwan Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 60. Taiwan Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 61. Taiwan Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 62. Taiwan Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. Australia Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 64. Australia Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 65. Australia Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 66. Australia Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 71. Europe Respiratory Drugs, by Country USD Million (2015-2020)
  • Table 72. Europe Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 73. Europe Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 74. Europe Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 75. Europe Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. Germany Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 77. Germany Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 78. Germany Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 79. Germany Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 80. France Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 81. France Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 82. France Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 83. France Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 84. Italy Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 85. Italy Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 86. Italy Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 87. Italy Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 88. United Kingdom Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 89. United Kingdom Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 90. United Kingdom Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 91. United Kingdom Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. Netherlands Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 93. Netherlands Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 94. Netherlands Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 95. Netherlands Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 96. Rest of Europe Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 97. Rest of Europe Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 98. Rest of Europe Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 99. Rest of Europe Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 100. MEA Respiratory Drugs, by Country USD Million (2015-2020)
  • Table 101. MEA Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 102. MEA Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 103. MEA Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 104. MEA Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 105. Middle East Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 106. Middle East Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 107. Middle East Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 108. Middle East Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 109. Africa Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 110. Africa Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 111. Africa Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 112. Africa Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 113. North America Respiratory Drugs, by Country USD Million (2015-2020)
  • Table 114. North America Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 115. North America Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 116. North America Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 117. North America Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 118. United States Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 119. United States Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 120. United States Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 121. United States Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 122. Canada Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 123. Canada Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 124. Canada Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 125. Canada Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 126. Mexico Respiratory Drugs, by Type USD Million (2015-2020)
  • Table 127. Mexico Respiratory Drugs, by Disease Type USD Million (2015-2020)
  • Table 128. Mexico Respiratory Drugs, by End-users USD Million (2015-2020)
  • Table 129. Mexico Respiratory Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 130. Respiratory Drugs Sales: by Type(K Units)
  • Table 131. Respiratory Drugs Sales Antiasthmatic combinations , by Region K Units (2015-2020)
  • Table 132. Respiratory Drugs Sales Antihistamines , by Region K Units (2015-2020)
  • Table 133. Respiratory Drugs Sales Antitussives , by Region K Units (2015-2020)
  • Table 134. Respiratory Drugs Sales Bronchodilators , by Region K Units (2015-2020)
  • Table 135. Respiratory Drugs Sales Others , by Region K Units (2015-2020)
  • Table 136. Respiratory Drugs Sales: by Disease Type(K Units)
  • Table 137. Respiratory Drugs Sales Asthma , by Region K Units (2015-2020)
  • Table 138. Respiratory Drugs Sales COPD , by Region K Units (2015-2020)
  • Table 139. Respiratory Drugs Sales Allergic rhinitis , by Region K Units (2015-2020)
  • Table 140. Respiratory Drugs Sales Cystic fibrosis , by Region K Units (2015-2020)
  • Table 141. Respiratory Drugs Sales Idiopathic pulmonary fibrosis , by Region K Units (2015-2020)
  • Table 142. Respiratory Drugs Sales Other respiratory disorders , by Region K Units (2015-2020)
  • Table 143. Respiratory Drugs Sales: by End-users(K Units)
  • Table 144. Respiratory Drugs Sales Hospitals , by Region K Units (2015-2020)
  • Table 145. Respiratory Drugs Sales Clinics , by Region K Units (2015-2020)
  • Table 146. Respiratory Drugs Sales Others , by Region K Units (2015-2020)
  • Table 147. Respiratory Drugs Sales: by Distribution Channel(K Units)
  • Table 148. Respiratory Drugs Sales Online Channel , by Region K Units (2015-2020)
  • Table 149. Respiratory Drugs Sales Offline Channel , by Region K Units (2015-2020)
  • Table 150. South America Respiratory Drugs Sales, by Country K Units (2015-2020)
  • Table 151. South America Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 152. South America Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 153. South America Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 154. South America Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 155. Brazil Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 156. Brazil Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 157. Brazil Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 158. Brazil Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 159. Argentina Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 160. Argentina Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 161. Argentina Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 162. Argentina Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 163. Rest of South America Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 164. Rest of South America Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 165. Rest of South America Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 166. Rest of South America Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 167. Asia Pacific Respiratory Drugs Sales, by Country K Units (2015-2020)
  • Table 168. Asia Pacific Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 169. Asia Pacific Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 170. Asia Pacific Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 171. Asia Pacific Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 172. China Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 173. China Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 174. China Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 175. China Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 176. Japan Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 177. Japan Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 178. Japan Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 179. Japan Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 180. India Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 181. India Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 182. India Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 183. India Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 184. South Korea Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 185. South Korea Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 186. South Korea Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 187. South Korea Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 188. Taiwan Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 189. Taiwan Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 190. Taiwan Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 191. Taiwan Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 192. Australia Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 193. Australia Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 194. Australia Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 195. Australia Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 196. Rest of Asia-Pacific Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 197. Rest of Asia-Pacific Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 198. Rest of Asia-Pacific Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 199. Rest of Asia-Pacific Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 200. Europe Respiratory Drugs Sales, by Country K Units (2015-2020)
  • Table 201. Europe Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 202. Europe Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 203. Europe Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 204. Europe Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 205. Germany Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 206. Germany Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 207. Germany Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 208. Germany Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 209. France Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 210. France Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 211. France Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 212. France Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 213. Italy Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 214. Italy Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 215. Italy Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 216. Italy Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 217. United Kingdom Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 218. United Kingdom Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 219. United Kingdom Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 220. United Kingdom Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 221. Netherlands Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 222. Netherlands Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 223. Netherlands Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 224. Netherlands Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 225. Rest of Europe Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 226. Rest of Europe Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 227. Rest of Europe Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 228. Rest of Europe Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 229. MEA Respiratory Drugs Sales, by Country K Units (2015-2020)
  • Table 230. MEA Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 231. MEA Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 232. MEA Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 233. MEA Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 234. Middle East Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 235. Middle East Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 236. Middle East Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 237. Middle East Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 238. Africa Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 239. Africa Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 240. Africa Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 241. Africa Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 242. North America Respiratory Drugs Sales, by Country K Units (2015-2020)
  • Table 243. North America Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 244. North America Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 245. North America Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 246. North America Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 247. United States Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 248. United States Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 249. United States Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 250. United States Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 251. Canada Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 252. Canada Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 253. Canada Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 254. Canada Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 255. Mexico Respiratory Drugs Sales, by Type K Units (2015-2020)
  • Table 256. Mexico Respiratory Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 257. Mexico Respiratory Drugs Sales, by End-users K Units (2015-2020)
  • Table 258. Mexico Respiratory Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 259. Respiratory Drugs: by Type(USD/Units)
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Respiratory Drugs: by Type(USD Million)
  • Table 269. Respiratory Drugs Antiasthmatic combinations , by Region USD Million (2021-2026)
  • Table 270. Respiratory Drugs Antihistamines , by Region USD Million (2021-2026)
  • Table 271. Respiratory Drugs Antitussives , by Region USD Million (2021-2026)
  • Table 272. Respiratory Drugs Bronchodilators , by Region USD Million (2021-2026)
  • Table 273. Respiratory Drugs Others , by Region USD Million (2021-2026)
  • Table 274. Respiratory Drugs: by Disease Type(USD Million)
  • Table 275. Respiratory Drugs Asthma , by Region USD Million (2021-2026)
  • Table 276. Respiratory Drugs COPD , by Region USD Million (2021-2026)
  • Table 277. Respiratory Drugs Allergic rhinitis , by Region USD Million (2021-2026)
  • Table 278. Respiratory Drugs Cystic fibrosis , by Region USD Million (2021-2026)
  • Table 279. Respiratory Drugs Idiopathic pulmonary fibrosis , by Region USD Million (2021-2026)
  • Table 280. Respiratory Drugs Other respiratory disorders , by Region USD Million (2021-2026)
  • Table 281. Respiratory Drugs: by End-users(USD Million)
  • Table 282. Respiratory Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 283. Respiratory Drugs Clinics , by Region USD Million (2021-2026)
  • Table 284. Respiratory Drugs Others , by Region USD Million (2021-2026)
  • Table 285. Respiratory Drugs: by Distribution Channel(USD Million)
  • Table 286. Respiratory Drugs Online Channel , by Region USD Million (2021-2026)
  • Table 287. Respiratory Drugs Offline Channel , by Region USD Million (2021-2026)
  • Table 288. South America Respiratory Drugs, by Country USD Million (2021-2026)
  • Table 289. South America Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 290. South America Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 291. South America Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 292. South America Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 293. Brazil Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 294. Brazil Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 295. Brazil Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 296. Brazil Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 297. Argentina Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 298. Argentina Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 299. Argentina Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 300. Argentina Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 301. Rest of South America Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 302. Rest of South America Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 303. Rest of South America Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 304. Rest of South America Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 305. Asia Pacific Respiratory Drugs, by Country USD Million (2021-2026)
  • Table 306. Asia Pacific Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 307. Asia Pacific Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 308. Asia Pacific Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 309. Asia Pacific Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 310. China Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 311. China Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 312. China Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 313. China Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 314. Japan Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 315. Japan Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 316. Japan Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 317. Japan Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 318. India Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 319. India Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 320. India Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 321. India Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 322. South Korea Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 323. South Korea Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 324. South Korea Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 325. South Korea Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 326. Taiwan Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 327. Taiwan Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 328. Taiwan Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 329. Taiwan Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 330. Australia Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 331. Australia Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 332. Australia Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 333. Australia Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 334. Rest of Asia-Pacific Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 335. Rest of Asia-Pacific Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 336. Rest of Asia-Pacific Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 337. Rest of Asia-Pacific Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 338. Europe Respiratory Drugs, by Country USD Million (2021-2026)
  • Table 339. Europe Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 340. Europe Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 341. Europe Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 342. Europe Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 343. Germany Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 344. Germany Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 345. Germany Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 346. Germany Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 347. France Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 348. France Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 349. France Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 350. France Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 351. Italy Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 352. Italy Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 353. Italy Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 354. Italy Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 355. United Kingdom Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 356. United Kingdom Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 357. United Kingdom Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 358. United Kingdom Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 359. Netherlands Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 360. Netherlands Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 361. Netherlands Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 362. Netherlands Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 363. Rest of Europe Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 364. Rest of Europe Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 365. Rest of Europe Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 366. Rest of Europe Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 367. MEA Respiratory Drugs, by Country USD Million (2021-2026)
  • Table 368. MEA Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 369. MEA Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 370. MEA Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 371. MEA Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 372. Middle East Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 373. Middle East Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 374. Middle East Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 375. Middle East Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 376. Africa Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 377. Africa Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 378. Africa Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 379. Africa Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 380. North America Respiratory Drugs, by Country USD Million (2021-2026)
  • Table 381. North America Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 382. North America Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 383. North America Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 384. North America Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 385. United States Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 386. United States Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 387. United States Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 388. United States Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 389. Canada Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 390. Canada Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 391. Canada Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 392. Canada Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 393. Mexico Respiratory Drugs, by Type USD Million (2021-2026)
  • Table 394. Mexico Respiratory Drugs, by Disease Type USD Million (2021-2026)
  • Table 395. Mexico Respiratory Drugs, by End-users USD Million (2021-2026)
  • Table 396. Mexico Respiratory Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 397. Respiratory Drugs Sales: by Type(K Units)
  • Table 398. Respiratory Drugs Sales Antiasthmatic combinations , by Region K Units (2021-2026)
  • Table 399. Respiratory Drugs Sales Antihistamines , by Region K Units (2021-2026)
  • Table 400. Respiratory Drugs Sales Antitussives , by Region K Units (2021-2026)
  • Table 401. Respiratory Drugs Sales Bronchodilators , by Region K Units (2021-2026)
  • Table 402. Respiratory Drugs Sales Others , by Region K Units (2021-2026)
  • Table 403. Respiratory Drugs Sales: by Disease Type(K Units)
  • Table 404. Respiratory Drugs Sales Asthma , by Region K Units (2021-2026)
  • Table 405. Respiratory Drugs Sales COPD , by Region K Units (2021-2026)
  • Table 406. Respiratory Drugs Sales Allergic rhinitis , by Region K Units (2021-2026)
  • Table 407. Respiratory Drugs Sales Cystic fibrosis , by Region K Units (2021-2026)
  • Table 408. Respiratory Drugs Sales Idiopathic pulmonary fibrosis , by Region K Units (2021-2026)
  • Table 409. Respiratory Drugs Sales Other respiratory disorders , by Region K Units (2021-2026)
  • Table 410. Respiratory Drugs Sales: by End-users(K Units)
  • Table 411. Respiratory Drugs Sales Hospitals , by Region K Units (2021-2026)
  • Table 412. Respiratory Drugs Sales Clinics , by Region K Units (2021-2026)
  • Table 413. Respiratory Drugs Sales Others , by Region K Units (2021-2026)
  • Table 414. Respiratory Drugs Sales: by Distribution Channel(K Units)
  • Table 415. Respiratory Drugs Sales Online Channel , by Region K Units (2021-2026)
  • Table 416. Respiratory Drugs Sales Offline Channel , by Region K Units (2021-2026)
  • Table 417. South America Respiratory Drugs Sales, by Country K Units (2021-2026)
  • Table 418. South America Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 419. South America Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 420. South America Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 421. South America Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 422. Brazil Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 423. Brazil Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 424. Brazil Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 425. Brazil Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 426. Argentina Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 427. Argentina Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 428. Argentina Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 429. Argentina Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 430. Rest of South America Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 431. Rest of South America Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 432. Rest of South America Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 433. Rest of South America Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 434. Asia Pacific Respiratory Drugs Sales, by Country K Units (2021-2026)
  • Table 435. Asia Pacific Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 436. Asia Pacific Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 437. Asia Pacific Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 438. Asia Pacific Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 439. China Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 440. China Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 441. China Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 442. China Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 443. Japan Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 444. Japan Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 445. Japan Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 446. Japan Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 447. India Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 448. India Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 449. India Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 450. India Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 451. South Korea Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 452. South Korea Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 453. South Korea Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 454. South Korea Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 455. Taiwan Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 456. Taiwan Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 457. Taiwan Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 458. Taiwan Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 459. Australia Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 460. Australia Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 461. Australia Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 462. Australia Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 463. Rest of Asia-Pacific Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 464. Rest of Asia-Pacific Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 465. Rest of Asia-Pacific Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 466. Rest of Asia-Pacific Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 467. Europe Respiratory Drugs Sales, by Country K Units (2021-2026)
  • Table 468. Europe Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 469. Europe Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 470. Europe Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 471. Europe Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 472. Germany Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 473. Germany Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 474. Germany Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 475. Germany Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 476. France Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 477. France Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 478. France Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 479. France Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 480. Italy Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 481. Italy Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 482. Italy Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 483. Italy Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 484. United Kingdom Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 485. United Kingdom Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 486. United Kingdom Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 487. United Kingdom Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 488. Netherlands Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 489. Netherlands Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 490. Netherlands Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 491. Netherlands Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 492. Rest of Europe Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 493. Rest of Europe Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 494. Rest of Europe Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 495. Rest of Europe Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 496. MEA Respiratory Drugs Sales, by Country K Units (2021-2026)
  • Table 497. MEA Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 498. MEA Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 499. MEA Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 500. MEA Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 501. Middle East Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 502. Middle East Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 503. Middle East Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 504. Middle East Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 505. Africa Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 506. Africa Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 507. Africa Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 508. Africa Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 509. North America Respiratory Drugs Sales, by Country K Units (2021-2026)
  • Table 510. North America Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 511. North America Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 512. North America Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 513. North America Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 514. United States Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 515. United States Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 516. United States Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 517. United States Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 518. Canada Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 519. Canada Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 520. Canada Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 521. Canada Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 522. Mexico Respiratory Drugs Sales, by Type K Units (2021-2026)
  • Table 523. Mexico Respiratory Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 524. Mexico Respiratory Drugs Sales, by End-users K Units (2021-2026)
  • Table 525. Mexico Respiratory Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 526. Respiratory Drugs: by Type(USD/Units)
  • Table 527. Research Programs/Design for This Report
  • Table 528. Key Data Information from Secondary Sources
  • Table 529. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Respiratory Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Respiratory Drugs: by Disease Type USD Million (2015-2020)
  • Figure 6. Global Respiratory Drugs: by End-users USD Million (2015-2020)
  • Figure 7. Global Respiratory Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Respiratory Drugs Share (%), by Country
  • Figure 9. Asia Pacific Respiratory Drugs Share (%), by Country
  • Figure 10. Europe Respiratory Drugs Share (%), by Country
  • Figure 11. MEA Respiratory Drugs Share (%), by Country
  • Figure 12. North America Respiratory Drugs Share (%), by Country
  • Figure 13. Global Respiratory Drugs: by Type K Units (2015-2020)
  • Figure 14. Global Respiratory Drugs: by Disease Type K Units (2015-2020)
  • Figure 15. Global Respiratory Drugs: by End-users K Units (2015-2020)
  • Figure 16. Global Respiratory Drugs: by Distribution Channel K Units (2015-2020)
  • Figure 17. South America Respiratory Drugs Share (%), by Country
  • Figure 18. Asia Pacific Respiratory Drugs Share (%), by Country
  • Figure 19. Europe Respiratory Drugs Share (%), by Country
  • Figure 20. MEA Respiratory Drugs Share (%), by Country
  • Figure 21. North America Respiratory Drugs Share (%), by Country
  • Figure 22. Global Respiratory Drugs: by Type USD/Units (2015-2020)
  • Figure 23. Global Respiratory Drugs share by Players 2020 (%)
  • Figure 24. Global Respiratory Drugs share by Players (Top 3) 2020(%)
  • Figure 25. Global Respiratory Drugs share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2020
  • Figure 31. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 32. 3M (United States) Revenue: by Geography 2020
  • Figure 33. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Novartis AG (Switzerland), Revenue, Net Income and Gross profit
  • Figure 38. Novartis AG (Switzerland), Revenue: by Geography 2020
  • Figure 39. Omron Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Omron Corporation (Japan) Revenue: by Geography 2020
  • Figure 41. Sunovion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Sunovion Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Global Respiratory Drugs: by Type USD Million (2021-2026)
  • Figure 44. Global Respiratory Drugs: by Disease Type USD Million (2021-2026)
  • Figure 45. Global Respiratory Drugs: by End-users USD Million (2021-2026)
  • Figure 46. Global Respiratory Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 47. South America Respiratory Drugs Share (%), by Country
  • Figure 48. Asia Pacific Respiratory Drugs Share (%), by Country
  • Figure 49. Europe Respiratory Drugs Share (%), by Country
  • Figure 50. MEA Respiratory Drugs Share (%), by Country
  • Figure 51. North America Respiratory Drugs Share (%), by Country
  • Figure 52. Global Respiratory Drugs: by Type K Units (2021-2026)
  • Figure 53. Global Respiratory Drugs: by Disease Type K Units (2021-2026)
  • Figure 54. Global Respiratory Drugs: by End-users K Units (2021-2026)
  • Figure 55. Global Respiratory Drugs: by Distribution Channel K Units (2021-2026)
  • Figure 56. South America Respiratory Drugs Share (%), by Country
  • Figure 57. Asia Pacific Respiratory Drugs Share (%), by Country
  • Figure 58. Europe Respiratory Drugs Share (%), by Country
  • Figure 59. MEA Respiratory Drugs Share (%), by Country
  • Figure 60. North America Respiratory Drugs Share (%), by Country
  • Figure 61. Global Respiratory Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Boehringer Ingelheim GmbH (Germany)
  • 3M (United States)
  • AstraZeneca plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Novartis AG (Switzerland),
  • Omron Corporation (Japan)
  • Sunovion Pharmaceuticals Inc. (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 208 Pages 59 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Respiratory Drugs Quantitative research analysis
Global Respiratory Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Respiratory Diseases " is seen as one of major growth factors of Respiratory Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Global will lead Respiratory Drugs Market in coming years.

Know More About Global Respiratory Drugs Report?

Have a Query? Click Here

Other Related Reports

Pasireotide Comprehensive Study by Form (Liquid Solution, Powder), Dosage (0.3mg/ml, 0.6mg/ml, 0.9mg/ml), End User (Hospital, Pharmacy) Players and Region - Americas Market Outlook to 2026
$ 3500
Adenosine Deaminase Deficiency Drugs Comprehensive Study by Type (Adagen, Revcovi), Application (Hospitals, Clinic, Ambulatory Surgical Centers), Sales Channel (Prescription Drugs, Over-the-Counter D...
$ 3500
Bio-protein Drug Comprehensive Study by Type (Monoclonal Antibodies, Recombinant Protein, Therapeutic Proteins, Vaccines), Application (Pharma and Biotech Companies, Clinical Research Organizations, ...
$ 3650
Sumatriptan Succinate Comprehensive Study by Application (Migraine, Cluster Headache), Mode Of Administration (Oral, Subcutaneous Injection), Form (Tablet, Injection, Spray), Distribution Channel (On...
$ 3450
Biopharmaceutical Logistics - Comprehensive Study by Type (Cold-chain Transport, Non-Cold-chain Transport.), Storage (Storage, Transportation, Monitoring Components), Transportation (Air Shipping, Ra...
$ 3650
Antimicrobial Gel Comprehensive Study by Type (Silver Antimicrobial Gel, Iodine Antimicrobial Gel, Others), Application (Home Use, Hospital Use), Distribution Channel (Hospital Pharmacies, Retail Pha...
$ 3350